Innoviva

Q4 2025 -2.73%Q3 2025 +13.12%Q2 2025 +1.04%Q1 2025 -0.91%Q4 2024 -1.96%Q3 2024 +2.93%Q2 2024 +1.58%Q1 2024 -1.55%Q4 2023 -0.72%Q3 2023 +7.01%Q2 2023 -1.35%Q1 2023 +4.45%Q4 2022 -5.17%Q3 2022 +5.06%Q2 2022 -1.73%Q1 2022 +0.93%Q4 2021 +13.71%Q3 2021 +8.80%Q2 2021 +6.33%Q1 2021 +0.86%Q4 2020 +0.97%Q3 2020 +11.32%Q2 2020 +0.44%Q1 2020 +5.27%Q4 2019 +3.50%Q3 2019 +6.22%Q2 2019 -15.08%Q1 2019 +6.49%Q4 2018 -3.31%Q3 2018 +2.28%Q2 2018 -1.22%Q1 2018 -2.87%Q4 2017 +8.51%Q3 2017 -11.88%Q2 2017 +4.35%Q1 2017 -8.29%Q4 2016 +1.74%Q3 2016 -1.64%Q2 2016 +9.16%Q1 2016 -1.04%Q4 2015 +14.55%Q3 2015 +1.15%Q2 2015 -10.82%Q1 2015 -6.27%Q4 2014 +10.84%Q3 2014 -5.01%Q2 2014 +4.52%Q1 2014 -1.10%Q4 2013 -2.08%Q3 2013 +8.29%Q2 2013 -3.68%Q1 2013 +11.33%Q4 2012 -4.92%Q3 2012 -9.42%Q2 2012 -7.07%Q1 2011 -1.87%Q1 2012 +19.44%Q4 2011 +0.77%Q3 2011 +8.64%Q2 2011 +1.35%Q4 2010 -1.05%Q3 2010 +2.74%Q2 2010 +7.98%Q1 2010 -9.20%

Jul 29, 2020

•

Jun 30, 2020

Innoviva Q2 2020 Earnings Report

Reported financial results for the second quarter ended June 30, 2020.

Key Takeaways

Innoviva reported its Q2 2020 financial results, noting a decrease in RELVAR®/BREO® ELLIPTA® global net sales by 3% year-over-year, while ANORO® ELLIPTA® global net sales increased by 5%. TRELEGY® ELLIPTA® global net sales were $240.5 million compared to $151.4 million in the same period last year.

RELVAR®/BREO® ELLIPTA® global net sales decreased by 3% compared to Q2 2019.

U.S. net sales of RELVAR®/BREO® ELLIPTA® decreased by 11% due to greater price discounting.

ANORO® ELLIPTA® global net sales increased by 5% compared to Q2 2019.

TRELEGY® ELLIPTA® global net sales were $240.5 million, compared to $151.4 million during comparable period a year ago.

Total Revenue

$78.9M

Previous year: $64.1M